About Bicycle Therapeutics plc
https://www.bicycletherapeutics.comBicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.
CEO
Kevin Lee
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 15
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Needham
Buy
HC Wainwright & Co.
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Oppenheimer
Outperform
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
BAKER BROS. ADVISORS LP
Shares:10.89M
Value:$72.06M
FCPM III SERVICES B.V.
Shares:3.45M
Value:$22.85M
ARMISTICE CAPITAL, LLC
Shares:2.98M
Value:$19.71M
Summary
Showing Top 3 of 109
About Bicycle Therapeutics plc
https://www.bicycletherapeutics.comBicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $11.73M ▲ | $77.28M ▲ | $-59.1M ▲ | -503.66% ▲ | $-0.85 ▲ | $-57.09M ▲ |
| Q2-2025 | $2.92M ▼ | $18.49M ▼ | $-78.95M ▼ | -2.7K% ▼ | $-1.14 ▼ | $-77.43M ▼ |
| Q1-2025 | $9.98M ▲ | $22.91M ▲ | $-60.75M ▼ | -608.94% ▲ | $-0.88 ▼ | $-70.2M ▼ |
| Q4-2024 | $3.71M ▲ | $15.3M ▼ | $-51.85M ▼ | -1.4K% ▲ | $-0.74 | $-65.96M ▼ |
| Q3-2024 | $2.68M | $20.87M | $-50.8M | -1.9K% | $-0.74 | $-61.21M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $648.33M ▼ | $763.95M ▼ | $145.47M ▼ | $618.48M ▼ |
| Q2-2025 | $721.45M ▼ | $832.18M ▼ | $163.27M ▲ | $668.91M ▼ |
| Q1-2025 | $792.97M ▼ | $883.89M ▼ | $143.56M ▼ | $740.33M ▼ |
| Q4-2024 | $879.52M ▼ | $956.87M ▼ | $163.81M ▼ | $793.06M ▼ |
| Q3-2024 | $890.86M | $996.75M | $165.71M | $831.03M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-59.1M ▲ | $-71.17M ▲ | $-674K ▼ | $-30K ▲ | $-73.13M ▼ | $-71.85M ▲ |
| Q2-2025 | $-78.95M ▼ | $-72.79M ▲ | $-498K ▲ | $-45K ▼ | $-71.52M ▲ | $-73.28M ▲ |
| Q1-2025 | $-60.99M ▼ | $-86.7M ▼ | $-606.32K ▼ | $-41.16K ▼ | $-86.55M ▼ | $-87.31M ▼ |
| Q4-2024 | $-51.85M ▼ | $-9.4M ▲ | $-368K ▲ | $203K ▲ | $-11.34M ▲ | $-9.76M ▲ |
| Q3-2024 | $-51.32M | $-39.83M | $-435K | $-31.93M | $-70.5M | $-40.27M |
CEO
Kevin Lee
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 15
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Needham
Buy
HC Wainwright & Co.
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Oppenheimer
Outperform
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
BAKER BROS. ADVISORS LP
Shares:10.89M
Value:$72.06M
FCPM III SERVICES B.V.
Shares:3.45M
Value:$22.85M
ARMISTICE CAPITAL, LLC
Shares:2.98M
Value:$19.71M
Summary
Showing Top 3 of 109